Novartis runs an annual program to support independent eye care initiatives worldwide via grant funding, including some in the world’s most remote areas and deprived communities.
Engineers spent two decades developing a new generation of contact lenses, Dailies Total1, to address the issue of discomfort users experience with existing silicone hydrogel lenses.
Efforts to improve health care in Africa take on many forms, the Novartis Institutes for BioMedical Research (NIBR) is contributing by discovering novel medicines that address patient needs.
Novartis has helped fight the disease by donating multidrug therapy (MDT) to leprosy patients worldwide through the World Health Organization.
Limited resources and other barriers have long stymied advances in medical research infrastructure in Africa. But the situation is starting to change. Many countries are making greater investments in science as part of broader efforts to tackle local health problems.
Novartis' Arogya Parivar initiative is a pioneering business approach which aims to deliver healthcare sustainably to more people, particularly in the developing world.
Novartis is proud to have achieved Silver Class status in this year’s edition of the RobecoSAM “Sustainability Yearbook” for our excellent sustainability performance.
Inclusion in the 2014 index acknowledges Novartis leadership in key areas of corporate responsibility. Companies named to the Global 100 are recognized as the top overall sustainability performers in their respective industries.
Africa Day at Novartis highlights the continent’s healthcare needs and efforts to address them.
Patients with multiple sclerosis, an autoimmune disease that affects 2.5 million worldwide, lose brain volume three to five times faster than people without the disease.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.